Celularity is a clinical-stage biotech company that derives therapies and commercial products from the postpartum human placenta. Its current revenue comes primarily from selling placental-derived biomaterial products — amniotic membrane allografts and connective tissue matrices — used in wound care, soft tissue repair, and reconstructive procedures. Key products include Biovance 3L and Rebound, sold through third-party distribution partners. Celularity also runs a biobanking service, collecting and storing umbilical cord blood and placental cells for families under a recurring fee model, and generates contract manufacturing revenue by offering its cGMP facility in Florham Park, NJ to third parties. The longer-term aspiration is to commercialize allogeneic, off-the-shelf cell therapies — primarily NK cells and mesenchymal-like adherent stromal cells (MLASCs) — targeting cancer, degenerative diseases, and age-related conditions. The cell therapy pipeline remains in clinical and pre-clinical development with no approved products. Celularity argues that deriving hundreds of doses from a single donor placenta makes its approach more scalable and cost-efficient than autologous therapies. Given capital constraints, Celularity is pursuing out-licensing and partnerships to advance its cell therapy programs rather than funding them internally.